Reporting owner · CIK 0001643875

Braunstein Scott

Visual SEC Form 4 history across 3 companies, 17 transactions and 3 filings.

DIRAtaiBeckley Inc.
Open-market mix
Latest filingSep 11, 2026, 09:44 PM
Filings3Form 4 records
Buying$6.5K1 purchases
Selling$00 sales
Net value$6.5KBuys minus sells
Companies34 securities
Most recentSep 11, 2026return

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Aug 24Feb 25Sep 26

Net value flow

Buys minus sells

Aug 24
$6.5K
Feb 25
$0
Sep 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$6.5K
Median P/S size$6.5K
Direct17
Indirect0
Sep 11, 2026return

Filing-only signals

Deterministic matches in this insider's history

Delayed Filingfiling-context1Derivative Transactionfiling-context10Director Buyrole1Direct Ownershipfiling-context13Large Holdings Increaseholdings1Large Holdings Reductionholdings110b5-1 Detectedfiling-context12

Latest Form 4 facts

Quick context from source filings

Latest transaction

buy at MARINUS PHARMACEUTICALS, INC. on Aug 14, 2024 valued at $6,526.

Review SEC filing
Latest buy

buy at MARINUS PHARMACEUTICALS, INC. on Aug 14, 2024 valued at $6,526.

Review SEC filing
Latest sale

No open-market insider sale is available.

Associated companies

Visual map of known reporting history

ATAIAtaiBeckley Inc.4 transactions · latest Sep 11, 2026, 09:44 PMCRBUCaribou Biosciences, Inc.1 transactions · latest Feb 22, 2025, 01:13 AMMRNSMARINUS PHARMACEUTICALS, INC.12 transactions · latest Feb 11, 2025, 02:11 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
MRNSBraunstein Scott
CHAIR
return10b5-1193k$0D
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/11/202502/11/2025
MRNSBraunstein Scott
CHAIR
return10b5-1360k$0D
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/11/202502/11/2025
MRNSBraunstein Scott
CHAIR
return10b5-1335k$0D
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/11/202502/11/2025
MRNSBraunstein Scott
CHAIR
return10b5-1167k$0D
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/11/202502/11/2025
MRNSBraunstein Scott
CHAIR
return10b5-1179k-$9.87MD
Direct Ownership 10b5-1 Detected
—02/11/202502/11/2025
MRNSBraunstein Scott
CHAIR
return10b5-1125k-$6.87MD
Direct Ownership Large Holdings Reduction 10b5-1 Detected
—02/11/202502/07/2025
MRNSBraunstein Scott
CHAIR
buy10b5-15.93k$652kP
Delayed Filing Director Buy Direct Ownership+1
—02/11/202508/14/2024

Braunstein Scott Insider Activity FAQ

SEC Form 4 context

Who is Braunstein Scott?

Braunstein Scott is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001643875.

Which companies has Braunstein Scott reported transactions for?

AtaiBeckley Inc., Caribou Biosciences, Inc., MARINUS PHARMACEUTICALS, INC.

When was Braunstein Scott's latest insider buy?

buy at MARINUS PHARMACEUTICALS, INC. on Aug 14, 2024 valued at $6,526.

When was Braunstein Scott's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.